Literature DB >> 10631078

BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice.

J A Streit1, T J Recker, J E Donelson, M E Wilson.   

Abstract

Cellular immune responses are required for protective immunity against Leishmania chagasi. Immunization strategies using live intracellular bacteria (e.g., bacille-Calmette Guerin strain of Mycobacterium bovis) expressing recombinant antigens can induce cellular immune responses to these antigens. Previous studies demonstrated that the L. chagasi antigen LCR1 stimulates IFN-gamma production from T cells of infected BALB/c mice, and immunization with recombinant LCR1 partially protects against L. chagasi infection. To determine whether live bacteria could enhance the immunization potential of LCR1, we engineered BCG expressing LCR1 (BCG-LCR1). Subcutaneous immunization with BCG-LCR1, but not with BCG containing plasmid only (BCG-pMV261), elicited better protective immunity against L. chagasi infection than LCR1 protein alone. BCG-LCR1 administered intraperitoneally did not protect. Splenocytes from mice immunized s.c. with either BCG-LCR1 or BCG-pMV261 and then infected with L. chagasi promastigotes had increased antigen-induced IFN-gamma and reduced IL-10 production compared to splenocytes of control mice. We propose that BCG-LCR1 promotes a Th1-type protective immune response, and it may be a useful component of a Leishmania vaccine. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10631078     DOI: 10.1006/expr.1999.4459

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  13 in total

1.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

Review 3.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 4.  The development and clinical evaluation of second-generation leishmaniasis vaccines.

Authors:  Malcolm S Duthie; Vanitha S Raman; Franco M Piazza; Steven G Reed
Journal:  Vaccine       Date:  2011-11-12       Impact factor: 3.641

5.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

6.  gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

Authors:  Swati Bhowmick; Rajesh Ravindran; Nahid Ali
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

Review 7.  Manipulation of BCG vaccine: a double-edged sword.

Authors:  V K Singh; R Srivastava; B S Srivastava
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-25       Impact factor: 3.267

Review 8.  Present status of antileishmanial vaccines.

Authors:  Monidipa Ghosh; Santu Bandyopadhyay
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

9.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

10.  Identification of proteins in promastigote and amastigote-like Leishmania using an immunoproteomic approach.

Authors:  Vinicio T S Coelho; Jamil S Oliveira; Diogo G Valadares; Miguel A Chávez-Fumagalli; Mariana C Duarte; Paula S Lage; Manuel Soto; Marcelo M Santoro; Carlos A P Tavares; Ana Paula Fernandes; Eduardo A F Coelho
Journal:  PLoS Negl Trop Dis       Date:  2012-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.